Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
biote
BTMD
biote
Regulatory Risks Will Limit Hormone Therapy But Telemedicine Will Help
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
30 May 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.50
7.7% undervalued
intrinsic discount
20 Aug
US$3.23
Loading
1Y
-47.3%
7D
7.0%
Author's Valuation
US$3.5
7.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.5
7.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-3m
199m
2019
2021
2023
2025
2027
2028
Revenue US$147.4m
Earnings US$7.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.88%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$6.99m
Earnings '28
x
20.42x
PE Ratio '28
=
US$142.72m
Market Cap '28
US$142.72m
Market Cap '28
/
33.50m
No. shares '28
=
US$4.26
Share Price '28
US$4.26
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$3.50
Fair Value '25
